COVID-19 updates, including vaccine information, for our patients and visitors, Learn More
About Aaron Goodman, MD
Aaron Goodman, MD, is a hematologist and medical oncologist who specializes in treating a variety of blood cancers, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and multiple myeloma. He performs stem cell transplants for cancer treatment, including autologous (stem cells come from the individual receiving the transplant) and allogeneic (stem cells come from a matched donor) transplants.
Dr. Goodman treats and writes guidelines for the rare lymphoproliferative disorder Castleman disease. He also uses experimental therapeutics to treat people with rare histiocytosis, which is a group of syndromes characterized by an abnormal increase in the number of certain immune cells called histiocytes. They include Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease. Many of these novel therapies are designed to be more effective with less toxicity and targeted for individualized therapy.
Dr. Goodman also offers chimeric antigen receptor (CAR) T-cell therapy to adults with relapsed or refractory B-cell lymphoma, a type of non-Hodgkin lymphoma. CAR T-cell therapy harnesses the patient's own immune cells to recognize and kill cancer cells. It is just one of many types of personalized cancer therapies offered at UC San Diego Health. Dr. Goodman also has clinical and research interests in cutaneous and T-cell non-Hodgkin lymphomas (NHLs) and is part of the National Comprehensive Cancer Network (NCCN) guideline writing committee for both cutaneous NHLs and T-cell NHLs.
Working with the Department of Dermatology, he co-founded the first comprehensive cutaneous lymphoma clinic in San Diego. As an associate professor in the Department of Medicine, Dr. Goodman instructs medical students, residents and fellows at UC San Diego School of Medicine. His research interests include immunotherapy and cellular therapy treatment for hematologic malignancies and identifying biomarkers for response to immunotherapy. He has contributed book chapters to Early Phase Cancer Immunotherapy and Cancer Screening, and his work has been published in Oncology, Nature Reviews Clinical Oncology and Clinical Cancer Research, among others.
Dr. Goodman completed a fellowship in hematology/oncology at UC San Diego School of Medicine. He completed his residency at Washington University School of Medicine in St. Louis, Mo., where he was selected for his leadership and clinical abilities to serve as chief resident. He earned his medical degree at Emory University School of Medicine in Atlanta, Ga. He is board certified in internal medicine, medical oncology, and hematology.
Outside of work, Dr. Goodman enjoys spending time with his wife and three children. He plays rock guitar and classical piano and also stays active through running and hiking.
- Emory University, School of Medicine, Atlanta, GA
- Washington University, School of Medicine, St. Louis, MO
- UC San Diego, School of Medicine, San Diego, CA
Date Joined Staff
- American Board of Internal Medicine
- Medical Oncology
Conditions and Treatments
- Hematologic Malignancies
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Erdheim-Chester Disease
- Castleman Disease
- Blood and Marrow Stem Cell Transplantation
- Blood Cancer
- Multiple Myeloma
- Chimeric Antigen Receptor (CAR) T-Cell Therapy
- Autologous Stem Cell Transplant
- Allogeneic Stem Cell Transplant
- Cutaneous Lymphoma
- Stem Cells
- Stem Cell Transplantation for Hematologic and Non-Hematologic Indications
- Rosai-Dorfman Disease
- Langerhans Cell Histiocytosis
- We are proud to be ranked No. 1 in San Diego and No. 6 in California, with 10 top-ranked medical and surgical specialties — more than any hospital system in the region — according to the 2020-2021 U.S. News & World Report annual ranking.
- We’re making it safe to get your health care. Learn about the changes we’ve made in clinics and hospitals to get ready for patients who have delayed critical procedures or have urgent health needs.